<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lobomycosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lobomycosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lobomycosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jose Dario Martinez Villarreal, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fabio Francesconi, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ted Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H598356268">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lobomycosis is a chronic fungal infection of the skin and subcutaneous tissue that primarily occurs in tropical climates of Latin America. The causative organism is
         <em>
          Lacazia loboi
         </em>
         (formerly
         <em>
          Loboa loboi
         </em>
         ), a dimorphic fungus found in soil, vegetation, and water. Infection occurs through traumatic implantation of the fungus into the skin.
        </p>
        <p>
         The most common presentation in humans consists of slow-growing, keloid-like papules, nodules, or plaques in a localized area on exposed skin (
         <a class="graphic graphic_picture graphicRef96224 graphicRef96225 graphicRef96226" href="/z/d/graphic/96224.html" rel="external">
          picture 1A-C
         </a>
         ). Other manifestations of lobomycosis include ulcerated, infiltrative, verrucous, gumma-like, multifocal, and disseminated lesions.
        </p>
        <p>
         Although lobomycosis is the accepted term for this disorder, a variety of other names have been used to refer to lobomycosis [
         <a href="#rid1">
          1
         </a>
         ]. Examples include Jorge Lobo's disease, Jorge Lobo mycosis, Jorge Lobo blastomycosis, Amazonic pseudolepromatous blastomycosis, miraip or piraip ("burning" in the Tupi language), Caiabi leprosy, and lacaziosis.
        </p>
        <p>
         The clinical features, diagnosis, and management of lobomycosis will be reviewed here.
        </p>
        <p class="headingAnchor" id="H699577235">
         <span class="h1">
          ETIOLOGY AND TRANSMISSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The taxonomy of the fungus that causes lobomycosis has changed multiple times since the first description of the disease [
         <a href="#rid2">
          2-7
         </a>
         ]. The general consensus is that
         <em>
          L. loboi
         </em>
         is the preferred nomenclature [
         <a href="#rid8">
          8
         </a>
         ].
         <em>
          L. loboi
         </em>
         is a dimorphic fungus that may exist in a saprophytic phase in soil, vegetation, and water [
         <a href="#rid9">
          9
         </a>
         ]. Molecular analyses have demonstrated a relationship between
         <em>
          L. loboi
         </em>
         and other fungal members of the order Onygenales, including
         <em>
          Paracoccidioides brasiliensis
         </em>
         [
         <a href="#rid10">
          10
         </a>
         ]. Attempts to culture
         <em>
          L. loboi
         </em>
         in vitro have failed.
        </p>
        <p>
         Traumatic inoculation into the dermis is the most likely mode for the development of lobomycosis in humans, a concept that is supported by a report of lobomycosis that may have resulted from handling of
         <em>
          L. loboi
         </em>
         -infected mice [
         <a href="#rid11">
          11
         </a>
         ] and a report of lobomycosis in a laboratory scientist transmitted through experimental inoculation [
         <a href="#rid12">
          12
         </a>
         ]. In addition, patients have reported the development of symptoms following snakebites, insect bites, or stingray stings [
         <a href="#rid9">
          9,13
         </a>
         ]. Lobomycosis does not appear to spread through human to human transmission.
        </p>
        <p>
         <em>
          L. loboi
         </em>
         appears to have a long incubation period. The time period from inoculation to the development of a skin lesion is estimated to be one to two years [
         <a href="#rid11">
          11,14
         </a>
         ].
        </p>
        <p>
         Lobomycosis-like disease is a granulomatous disease of dolphins that was previously considered an expanding ecologic niche for lobomycosis [
         <a href="#rid15">
          15
         </a>
         ]. The proposed etiologic agent for lobomycosis-like disease is
         <em>
          Paracoccidioides ceti
         </em>
         , which would distinguish this disease from lobomycosis [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H699577265">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         After inoculation into the dermis, lobomycosis replicates slowly within macrophages [
         <a href="#rid16">
          16
         </a>
         ]. Preserved cellular immunity is probably necessary to hinder persistence and progression of the disease.
        </p>
        <p>
         Cytokines with suppressive effects on cellular immunity, particularly transforming growth factor-beta 1 (TGF-beta 1) and interleukin-10 (IL-10) may play key roles in the pathogenesis of lobomycosis. In a study that evaluated the expression of TGF-beta 1, IL-10, tumor necrosis factor-alpha (TNF-alpha), and inducible nitric oxide synthase (iNOS) in lesional skin from 16 patients with lobomycosis, TGF-beta 1 and IL-10 were the most frequently expressed cytokines [
         <a href="#rid17">
          17
         </a>
         ]. In contrast, expression of TNF-alpha, a proinflammatory cytokine, and iNOS, a marker of cellular immune response, was less prominent. Relevant immunosuppressive actions of TGF-beta may include suppression of phagocytic activity of macrophages and inhibition of nitric oxide and gamma interferon expression [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p>
         In addition, a study that used real-time polymerase chain reaction to assess expression of various cytokines in lesions of lobomycosis and healthy control skin found upregulation of regulatory T cell markers in lesional skin, suggesting that dominance of regulatory T cell activity in infected skin may contribute to persistent infection [
         <a href="#rid20">
          20
         </a>
         ]. Regulatory T cells might inhibit Th-dependent, protective responses to intracellular fungi.
        </p>
        <p>
         The possibility that impaired cellular immunity increases susceptibility to lobomycosis is also suggested by studies that utilized skin tests to assess immunologic function. Frequent absence of positive reactions to dinitrochlorobenzene sensitization, and reduced likelihood for positive skin reactions to
         <em>
          Staphylococcus
         </em>
         ,
         <em>
          Streptococcus
         </em>
         ,
         <em>
          Trichophyton
         </em>
         ,
         <em>
         </em>
         and
         <em>
          Candida
         </em>
         antigens, have been detected in patients with lobomycosis [
         <a href="#rid16">
          16,21
         </a>
         ]. Further study is necessary to clarify the role of the immune system in this disease.
        </p>
        <p>
         In addition to its immunosuppressive effects, TGF-beta may influence the clinical manifestations of lobomycosis. The profibrotic properties of TGF-beta may contribute to the classic keloid-like appearance of lobomycosis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598356274">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall prevalence of lobomycosis is low [
         <a href="#rid23">
          23
         </a>
         ]. The frequency of the disease varies based upon geographic location. Tropical regions of South America and Central America are the primary locales for lobomycosis. In particular, areas of dense forests with high annual rainfall (&gt;20 cm per year) and warm, humid environments (average temperature &gt;24°C) are the sites of greatest predilection for the disease [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Lobomycosis was first reported in 1931 by Jorge Lobo in Recife, Brazil, and continues to occur in Brazil [
         <a href="#rid25">
          25,26
         </a>
         ]. Examples of other South American and Central American countries in which lobomycosis has been reported include Colombia [
         <a href="#rid27">
          27-29
         </a>
         ], Suriname [
         <a href="#rid30">
          30
         </a>
         ], Venezuela [
         <a href="#rid9">
          9,31-35
         </a>
         ], Guyana, French Guiana [
         <a href="#rid36">
          36-38
         </a>
         ], Ecuador [
         <a href="#rid39">
          39
         </a>
         ], Peru [
         <a href="#rid40">
          40-42
         </a>
         ], Bolivia [
         <a href="#rid43">
          43
         </a>
         ], Panama [
         <a href="#rid44">
          44,45
         </a>
         ], Costa Rica [
         <a href="#rid46">
          46
         </a>
         ], and Mexico. Although most cases of lobomycosis occur in such tropical climates (eg, by the year 2000, only 3 of 465 reported human cases had occurred outside of the Amazon region [
         <a href="#rid47">
          47
         </a>
         ]), lobomycosis occasionally has been reported elsewhere. Reports have emerged from the United States [
         <a href="#rid48">
          48
         </a>
         ], Canada [
         <a href="#rid49">
          49
         </a>
         ], France [
         <a href="#rid50">
          50
         </a>
         ], the Netherlands [
         <a href="#rid51">
          51
         </a>
         ], Germany [
         <a href="#rid52">
          52
         </a>
         ], Greece [
         <a href="#rid53">
          53
         </a>
         ], and South Africa [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Lobomycosis occurs more frequently in men than in women and is most common in adults between the ages of 40 and 70 years [
         <a href="#rid54">
          54
         </a>
         ]. In a retrospective study of patients with lobomycosis in the state of Acre, Amazon region, Brazil, 219 of 249 patients (88 percent) were male [
         <a href="#rid54">
          54
         </a>
         ]. In endemic areas, lobomycosis most often occurs as an occupational infection and occasionally as a recreational infection in individuals exposed to harsh outdoor environments, such as forest workers, farmers, hunters, and fishermen [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598356286">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial lesion of lobomycosis is a superficial or deep-seated papule. Because of the prolonged incubation period, the papule may appear months to years after inoculation. Over the course of subsequent months to years, the area of involvement expands contiguously, leading to the formation of single or multiple monomorphic or polymorphic plaques or nodules that often resemble scars or keloids (
         <a class="graphic graphic_picture graphicRef96224 graphicRef96225 graphicRef96226" href="/z/d/graphic/96224.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid47">
          47
         </a>
         ]. The surface of the plaques and nodules is usually smooth, shiny, and intact, and the color usually ranges from skin colored to red-brown or wine-red. Telangiectasias may be present.
        </p>
        <p>
         Lobomycosis may also demonstrate a variety of other clinical characteristics, including dyschromia, ulceration, and infiltrative, verrucous, or gumma-like lesions (
         <a class="graphic graphic_picture graphicRef96627" href="/z/d/graphic/96627.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid56">
          56,57
         </a>
         ]. Dyschromia is common, and varies from hyperpigmentation to hypopigmentation and even achromia. Ulcers are most likely secondary to trauma and may be particularly likely to occur in sites of moist, macerated skin. Infiltrative lesions may resemble tuberculoid leprosy or burn scars (
         <a class="graphic graphic_picture graphicRef96227" href="/z/d/graphic/96227.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ]. Verrucous lobomycosis results from exophytic growth and may occur in longstanding disease, particularly on the lower extremities.
        </p>
        <p>
         Gumma-like lobomycosis is a rare presentation that presents as macular lesions with turgid borders, which evolve to form pustules, yellow exudate, and eventual scarring. This gumma-like phenomenon can occur several times in the same lesion and is associated with spontaneous resolution of the involved lesion [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Most often, the cutaneous manifestations of lobomycosis are limited to a localized area on a site of exposed skin. The most common sites are the pinna, upper limbs, and lower limbs [
         <a href="#rid1">
          1,59
         </a>
         ]. However, multifocal (multiple sites of involvement on a single limb) and disseminated presentations may also occur. In a retrospective study of 249 patients with lobomycosis in Brazil, localized, multifocal, and disseminated cutaneous lesions of lobomycosis were present in 61, 22, and 16 percent of patients, respectively [
         <a href="#rid54">
          54
         </a>
         ]. Regional lymph node enlargement, which may represent lymphatic spread of the fungus, is estimated to occur in 10 to 25 percent of patients [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Skin involvement from lobomycosis is usually asymptomatic. However, patients with extensive involvement may experience pruritus or dysesthesia.
        </p>
        <p class="headingAnchor" id="H22261343">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major histologic findings of lobomycosis are located in the epidermis and dermis. Although the epidermis may be normal or atrophic, transepidermal elimination of the fungus may be associated with acanthosis, hyperkeratosis, spongiosis, neutrophil collections, and hyperplastic follicular infundibula in some areas (
         <a class="graphic graphic_picture graphicRef96229" href="/z/d/graphic/96229.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid62">
          62,63
         </a>
         ]. In addition, ulcerated or verrucous presentations of lobomycosis will exhibit epidermal ulceration or significant epithelial hyperplasia consistent with these clinical presentations.
        </p>
        <p>
         The dermis exhibits a dense histiocytic dermal infiltrate composed of large numbers of epithelioid cells, multinucleated giant cells, and Langhans cells. Granulomas may or may not be present. In some cases, aggregates of large xanthomatous histiocytes with clear or finely granular eosinophilic cytoplasm (pseudo-Gaucher cells) are present [
         <a href="#rid62">
          62
         </a>
         ]. There is often a thin zone of collagen immediately beneath the epidermis that is spared from the inflammatory process in the dermis, a finding referred to as a Grenz zone or Unna band.
        </p>
        <p>
         The dermis also contains abundant fungal structures of
         <em>
          L. loboi
         </em>
         located within or outside of dermal macrophages (
         <a class="graphic graphic_picture graphicRef96231" href="/z/d/graphic/96231.html" rel="external">
          picture 5A
         </a>
         ). The fungal structures are round with birefringent membranes and thick walls containing melanin, and are best visualized with a silver stain or periodic acid-Schiff (PAS) stain (
         <a class="graphic graphic_picture graphicRef96228" href="/z/d/graphic/96228.html" rel="external">
          picture 5B
         </a>
         ). Each yeast cell approximates 6 to 12 micrometers in diameter. The fungus reproduces with simple gemmulation without exporulation, resulting in blastoconidia with chain-like or rosary-bead-like configurations [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Additional histologic findings of lobomycosis include lymphocytes in small to moderate numbers in the dermis (with a CD4:CD8 ratio of approximately 3:2), few or absent neutrophils, striking fibrosis, and asteroid bodies (star-shaped eosinophilic bodies within giant cells) [
         <a href="#rid47">
          47,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598356292">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of lobomycosis is often made years to decades after exposure, a phenomenon likely secondary to the slow progression of the disease and its often asymptomatic nature [
         <a href="#rid48">
          48,54
         </a>
         ]. In general, a diagnosis of lobomycosis should be considered in patients living in endemic areas who present with single or multiple keloid-like skin lesions located in cutaneous sites of predilection for this infection (eg, pinna, extremities, and other areas of exposed skin). Rarely, lobomycosis is diagnosed outside of an endemic area. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
         The diagnostic evaluation of patients with lobomycosis consists of both a clinical and microscopic examination. Although the clinical findings can suggest a diagnosis of lobomycosis, confirmation of the diagnosis requires microscopic visualization of fungal cells consistent with
         <em>
          L. loboi
         </em>
         .
        </p>
        <p class="headingAnchor" id="H22263448">
         <span class="h2">
          Clinical evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical evaluation of patients with lobomycosis should include a history of the course of lesion development (lobomycosis typically progresses slowly over the course of years) and a full skin examination to determine the extent of disease. In addition, palpation of regional lymph nodes and the tissue between the site of infection and regional lymph nodes should be performed. The detection of enlarged lymph nodes in the absence of another cause for lymphadenopathy in a patient with cutaneous lobomycosis supports a biopsy to assess for
         <em>
          L. loboi
         </em>
         within lymph nodes. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H22261317">
         <span class="h2">
          Microscopic confirmation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A skin biopsy is the gold standard procedure for confirming a diagnosis of lobomycosis [
         <a href="#rid55">
          55
         </a>
         ]. A specific antigen to confirm the presence of
         <em>
          L. loboi
         </em>
         in tissue has not been identified and the organism cannot be cultured in vitro.
        </p>
        <p class="headingAnchor" id="H22261238">
         <span class="h3">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A sample for histologic examination can be obtained through a punch biopsy or surgical excision. Visualization of structures consistent with
         <em>
          L. loboi
         </em>
         in the dermis confirms the diagnosis. The fungal forms are best visualized with a silver stain or periodic acid-Schiff (PAS) stain. (See
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques", section on 'Biopsy site preparation'
         </a>
         .)
        </p>
        <p>
         Characteristic features of lobomycosis include round yeast-like cells (approximately 6 x 13.5 x 11 micrometers) with a birefringent membrane and thick wall containing melanin (
         <a class="graphic graphic_picture graphicRef96231 graphicRef96228" href="/z/d/graphic/96231.html" rel="external">
          picture 5A-B
         </a>
         ). Individual fungal cells may be connected by short tubular projections forming 2 to 10 cell chains [
         <a href="#rid55">
          55
         </a>
         ]. A dense, dermal histiocytic infiltrate also is present. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H22263551">
         <span class="h3">
          Other techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a skin biopsy that demonstrates
         <em>
          L. loboi
         </em>
         in the dermis is the gold standard for confirming a diagnosis of lobomycosis, a biopsy is not always feasible, particularly in resource-limited settings. Limited data from case reports and a case series suggest that
         <em>
          L. loboi
         </em>
         may also be detected through fast and simple epidermal sampling techniques, such as a potassium hydroxide (KOH) preparation or exfoliative cytology. Transepidermal elimination of
         <em>
          L. loboi
         </em>
         from the dermis may account for the ability to detect
         <em>
          L. loboi
         </em>
         with these techniques [
         <a href="#rid62">
          62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potassium hydroxide preparation
         </strong>
         – In a potassium hydroxide (KOH) preparation, the surface of a lesion is scraped with a scalpel blade followed by placement on a glass slide with KOH. Microscopic examination is performed after the KOH solution dissolves epidermal keratinocytes [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">
          "Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The punch smear technique is an alternative approach that allows for assessment for
         <em>
          L. loboi
         </em>
         in the dermis. A 1 or 2 mm punch biopsy is taken from a skin lesion and placed on a glass slide. The epidermal portion of the specimen is removed with a scalpel. KOH is then placed on the specimen. After approximately 10 minutes, the specimen is crushed with a second glass slide. A coverslip is then placed on each slide, and both slides are examined with a microscope.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exfoliative cytology
         </strong>
         – In exfoliative cytology, scrapings from the surface of a lesion are examined under a microscope without the aid of KOH [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Similar to its appearance in skin biopsy specimens,
         <em>
          L. loboi
         </em>
         detected through these techniques appears as multiple round yeast-like bodies with thick walls that may be connected by small bridges, forming chains.
        </p>
        <p class="headingAnchor" id="H598356298">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of infectious disorders that can present with nodular or verrucous skin lesions similar to lobomycosis include leprosy (nodular variant), leishmaniasis (lepromatous variant), and some subcutaneous mycoses (eg, sporotrichosis, chromomycosis, and paracoccidioidomycosis). In all cases, a skin biopsy demonstrating fungal cells consistent with
         <em>
          L. loboi
         </em>
         easily distinguishes lobomycosis from these disorders.
        </p>
        <p>
         The nodular appearance of lobomycosis also requires differentiation from benign and malignant tumors. Because lobomycosis may closely resemble common keloids (
         <a class="graphic graphic_picture graphicRef96383 graphicRef96384" href="/z/d/graphic/96383.html" rel="external">
          picture 6A-B
         </a>
         ), clinicians in endemic areas should have a high suspicion for lobomycosis, particularly when a history of skin injury and preceding scar is absent. Unlike lobomycosis, a biopsy of a keloid is characterized by thick, eosinophilic collagen bundles in the dermis. The nodules and plaques of dermatofibrosarcoma protuberans (DFSP) may also resemble lobomycosis (
         <a class="graphic graphic_picture graphicRef96386" href="/z/d/graphic/96386.html" rel="external">
          picture 7
         </a>
         ). DFSP tends to occur on the trunk and proximal extremities and is characterized by pathologic findings of spindle cells in a storiform pattern. (See
         <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">
          "Keloids and hypertrophic scars"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7747.html" rel="external">
          "Dermatofibrosarcoma protuberans: Epidemiology, pathogenesis, clinical presentation, diagnosis, and staging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H598356304">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin involvement in lobomycosis typically continues to progress without treatment; therefore, treatment is generally indicated to improve quality of life (see
         <a class="local">
          'Prognosis'
         </a>
         below). The extent of disease influences the therapeutic approach. For patients with localized, surgically amenable disease, surgical excision is the preferred treatment.
        </p>
        <p>
         A variety of pharmacologic interventions have been attempted for the treatment of lobomycosis that cannot be surgically excised. However, results of pharmacologic treatments are often disappointing and data on the efficacy of these therapies are limited.
        </p>
        <p class="headingAnchor" id="H22257917">
         <span class="h2">
          Surgically amenable disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with localized lobomycosis are best managed with surgery. Wide surgical excision is the preferred first-line treatment. The intent is to remove all infected tissue, leaving the surgical margins clear of disease [
         <a href="#rid67">
          67
         </a>
         ]. Despite this intent, recurrences are common after surgical treatment [
         <a href="#rid9">
          9,54
         </a>
         ]. Surgery must be performed with care because the infection may be transmitted to areas of healthy skin via surgical instruments [
         <a href="#rid55">
          55,68
         </a>
         ].
        </p>
        <p>
         Other surgical techniques that have been reported effective in individual patients include cryosurgery and electrocauterization [
         <a href="#rid55">
          55
         </a>
         ]. Cryotherapy often requires multiple treatment sessions [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Some authors have used pharmacologic therapy in conjunction with surgery in an attempt to reduce the risk for recurrence after surgical procedures [
         <a href="#rid11">
          11
         </a>
         ]. However, the efficacy of such measures in comparison to surgery alone is unclear.
        </p>
        <p class="headingAnchor" id="H22257929">
         <span class="h2">
          Poor surgical candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of patients with nonsurgically amenable lobomycosis is difficult. There is no reliably effective treatment and treatment failure is common. Data are primarily limited to case reports. No high-quality therapeutic trials have been performed.
        </p>
        <p>
         Examples of treatment regimens that have been reported to be effective in case reports or other studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Itraconazole
         </strong>
         <strong>
          and
         </strong>
         <strong>
          clofazimine
         </strong>
         – Treatment of a facial lesion of lobomycosis for one year with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (100 mg per day) and
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         (100 mg per day) was associated with clinical and histopathologic remission [
         <a href="#rid52">
          52
         </a>
         ]. Relapse did not occur during a three-year follow-up period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posaconazole
         </strong>
         – A patient with lobomycosis involving the ear was treated with oral
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         (400 mg twice daily) for 27 months [
         <a href="#rid42">
          42
         </a>
         ]. Significant improvement was evident after four months of treatment. After 24 months, only postinflammatory hyperpigmentation remained. Although a biopsy specimen taken after 27 months showed persistent
         <em>
          L. loboi
         </em>
         cells, follow-up five years later showed no evidence of clinical recurrence. Posaconazole (400 mg twice daily) was also associated with partial improvement in a patient with disseminated lobomycosis associated with immunosuppression after a renal transplant [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Itraconazole
         </strong>
         <strong>
          and cryosurgery
         </strong>
         – A patient who developed a multifocal relapse of lobomycosis after surgery to treat the infection improved following five sessions of liquid nitrogen cryotherapy and oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (400 mg per day) [
         <a href="#rid67">
          67
         </a>
         ]. Follow-up at six months revealed almost complete regression of all lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple drug therapy for multibacillary leprosy
         </strong>
         – Observations suggesting improvement in concomitant lobomycosis in patients undergoing multiple drug therapy (MDT) for leprosy led to investigation of MDT for lobomycosis. In an unblinded study (n = 120), patients with lobomycosis were alternately assigned to one of two groups (MDT for four years or MDT plus
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         [100 mg twice daily] for four years) [
         <a href="#rid70">
          70
         </a>
         ]. MDT consisted of a monthly regimen of 600 mg of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , 300 mg of
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , and 100 mg of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         and daily treatment with 50 mg of clofazimine and 100 mg of dapsone. Surgical excision was also performed. Patients who did not adhere to therapy over time were reclassified as controls. Overall, response rates were similar in the two treatment groups, with improvement occurring in 52 of 80 patients (65 percent) and cure occurring in 20 (25 percent). The likelihood of cure was greater than the control group for both the MDT and MDT plus itraconazole groups (1.8, 95% CI 1.2-2.8 and 1.9, 95% CI 1.2-3, respectively). Some of the limitations of this study include the lack of randomization and a high rate of treatment discontinuation in the MDT plus itraconazole group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trimethoprim-sulfamethoxazole
         </strong>
         – A combination of surgical excision and a five-month course of
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (160/800 mg given twice daily) was associated with marked improvement of lobomycosis on the ear. No clinical signs of recurrence were detected at a follow-up visit at six months.
        </p>
        <p>
        </p>
        <p>
         Treatments with
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         [
         <a href="#rid43">
          43,71,72
         </a>
         ], amphotericin B [
         <a href="#rid73">
          73
         </a>
         ], sulfa compounds [
         <a href="#rid74">
          74,75
         </a>
         ],
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         alone [
         <a href="#rid76">
          76-78
         </a>
         ], 5-fluorocytosine, and additional combination drug regimens have been attempted, but responses have been incomplete or poor. A complete response of lobomycosis has been reported in a dolphin treated with oral
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         An incidental finding of favorable responses of lobomycosis among 10 patients treated for concomitant leprosy in a dermatology department in Brazil may aid in the search for effective treatments for lobomycosis [
         <a href="#rid54">
          54
         </a>
         ]. The patients noted softening and/or reduced pruritus in lobomycosis lesions during treatment for multibacillary leprosy (rifampicin,
         <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">
          clofazimine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H598356310">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical course of lobomycosis is characterized by slow, progressive involvement of the skin and subcutaneous tissue. Lymph node involvement may be present. Although involvement of internal organs does not occur, extensive or disseminated skin disease can cause local tissue destruction and physical disability. Spontaneous resolution is rare [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Squamous cell carcinoma is a rare complication of lobomycosis. A few case reports document the development of squamous cell carcinoma in sites of longstanding lobomycosis [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598356316">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term follow-up is mandatory since there is a high relapse rate in lobomycosis [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598356322">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and transmission
         </strong>
         – Lobomycosis is a chronic fungal infection of the skin and subcutaneous tissue that may affect humans and dolphins.
         <em>
          Lacazia loboi
         </em>
         , a dimorphic fungus found in soil, vegetation, and water, is the causative agent. Traumatic implantation of the fungus into the skin is considered the most likely mode of transmission. (See
         <a class="local">
          'Etiology and transmission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Lobomycosis most frequently occurs in tropical climates of South America and Central America. Lobomycosis is occasionally diagnosed elsewhere. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Course
         </strong>
         – Lobomycosis is characterized by a slow and progressive clinical course. The initial skin lesion often does not appear until one to two years after inoculation. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Skin findings
         </strong>
         – The initial skin lesion of lobomycosis is usually a papule that expands to form keloid-like nodules or plaques (
         <a class="graphic graphic_picture graphicRef96224 graphicRef96225 graphicRef96226" href="/z/d/graphic/96224.html" rel="external">
          picture 1A-C
         </a>
         ). Ulcerated, infiltrative, verrucous, and gumma-like presentations also may occur. The most common sites for lesion development are the pinna, upper limbs, and lower limbs. Localized lobomycosis is most common, but multifocal and disseminated presentations may occur. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A diagnosis of lobomycosis is confirmed by recognition of fungal cells consistent with
         <em>
          L. loboi
         </em>
         in the skin (
         <a class="graphic graphic_picture graphicRef96228" href="/z/d/graphic/96228.html" rel="external">
          picture 5B
         </a>
         ). Skin biopsy is the gold standard test.
         <em>
          L. loboi
         </em>
         may also be detected through superficial epidermal sampling techniques. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – The treatment of lobomycosis can be challenging:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery feasible
         </strong>
         – For patients with localized disease that is surgically amenable, we suggest surgical excision as the first-line treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative surgical therapies that may be beneficial are cryotherapy and electrocauterization. (See
         <a class="local">
          'Surgically amenable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery not feasible
         </strong>
         – The treatment of lobomycosis that cannot be surgically managed is particularly difficult. A variety of pharmacologic treatments have been attempted with mixed results. Data on the efficacy of these treatments are limited and the optimum approach to pharmacologic treatment of lobomycosis is unclear. (See
         <a class="local">
          'Poor surgical candidates'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          da Lacaz CS, Porto E, Martins JE, et al. Doença de Jorge Lobo. In: Tratado de Micologia Médica Lacaz, 9th ed, Sarvier, 2002. p.462.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca Filho O, Arêa Leão AE. Contribuição para o conhecimento das granulomatoses blastomicoides. O agente etiológico da doença de Jorge Lobo. Rev Med Cirurg Brasil 1940; 48:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca Filho O, Arêa Leão AE. Contribuição para o conhecimento das granulomatoses blastomicoides. O agente etiológico da doença de Jorge Lobo. Bol Acad Nac Med 1940; 112:42.
          </a>
         </li>
         <li class="breakAll">
          Fonseca Filho O. Glenosporella loboi. In: Parasitologia Médica Parasitos e Doenças Parasitárias do Homem, Fonseca Filho O (Ed), Guanabara Koogan, 1943. p.703.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida FP, da Lacaz CS. Blastomicose "tipo Jorge Lobo". An Fac Med Univ Sao Paulo 1948-1949; 24:5.
          </a>
         </li>
         <li class="breakAll">
          Langeron M, Vanbreuseghem R. La blastomycose chéloidienne ou maladie die Jorge Lobo. In: Précis de Mycologie, 2nd ed, Langeron M, Vanbreuseghem R (Eds), Masson, 1952. p.490.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borelli D. Lobomicosis: nomenclatura de su agente (revisión critica). Med Cutanea 1968; 3:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taborda PR, Taborda VA, McGinnis MR. Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis. J Clin Microbiol 1999; 37:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, et al. Lobomycosis: an emerging disease in humans and delphinidae. Mycoses 2012; 55:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salgado CG, Tavares LS, Plautz HL, et al. Enzymatic isolation of Lacazia loboi cells from skin lesions of lobomycosis. Med Mycol 2009; 47:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosa PS, Soares CT, Belone Ade F, et al. Accidental Jorge Lobo's disease in a worker dealing with Lacazia loboi infected mice: a case report. J Med Case Rep 2009; 3:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borelli D. Lobomicosis experimental. Dermatol Venez 1962; 3:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo-Aasen I. Blastomicosis queloidiana o enfermedad de Jorge Lobo en Venezuela. Dermatol Venez 1958; 1:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opromolla DV, Nogueira ME. Inoculation of Lacazia loboi into the subcutaneous tissue of the hamster cheek pouch. Rev Inst Med Trop Sao Paulo 2000; 42:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilela R, Bossart GD, St Leger JA, et al. Cutaneous Granulomas in Dolphins Caused by Novel Uncultivated Paracoccidioides brasiliensis. Emerg Infect Dis 2016; 22:2063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecher SA, Croce J, Ferri RG. Study of humoral and cellular immunity in lobomycosis. Allergol Immunopathol (Madr) 1979; 7:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilani-Moreno FR, Belone Ade F, Lara VS, et al. Detection of cytokines and nitric oxide synthase in skin lesions of Jorge Lobo's disease patients. Med Mycol 2011; 49:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeltz RB, Chen J, Shevach EM. Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation. Immunology 2005; 114:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaresma JA, Lima LW, Fuzii HT, et al. Immunohistochemical evaluation of macrophage activity and its relationship with apoptotic cell death in the polar forms of leprosy. Microb Pathog 2010; 49:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azevedo Mde C, Rosa PS, Soares CT, et al. Analysis of Immune Response Markers in Jorge Lobo's Disease Lesions Suggests the Occurrence of Mixed T Helper Responses with the Dominance of Regulatory T Cell Activity. PLoS One 2015; 10:e0145814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecher SA, Fuchs J. Cellular immunity in lobomycosis (keloidal blastomycosis). Allergol Immunopathol (Madr) 1988; 16:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xavier MB, Libonati RM, Unger D, et al. Macrophage and TGF-beta immunohistochemical expression in Jorge Lobo's disease. Hum Pathol 2008; 39:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-E-Silva M, Aguiar-Santos-Vilela F, Cardoso-de-Brito A, Coelho-Carneiro S. Lobomycosis. Literature review and future perspectives. Actas Dermosifiliogr 2009; 100 Suppl 1:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borelli D. [The reservoir area of lobomycosis. Comments on the work of Dr. Carlos Peña on 2 Colombian cases]. Mycopathol Mycol Appl 1969; 37:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobo J. Um caso de blastomicose, produzido por uma espécie nova, encontrada em Recife. Rev Med Pernamb 1931; 1:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florian MC, Rodrigues DA, de Mendonça SBM, et al. Epidemiologic and Clinical Progression of Lobomycosis among Kaiabi Indians, Brazil, 1965-2019. Emerg Infect Dis 2020; 26:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Toro G. Lobomycosis. Int J Dermatol 1993; 32:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Toro G. Enfermedad de Jorge Lobo o blastomicosis queloidiana. Nuevos aspectos de la entidad en Colombia. Revisión Biomédica (Bogota) 1989; 9:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Toro G, Tellez N. Lobomycosis in Colombian Amer Indian patients. Mycopathologia 1992; 120:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reif JS, Peden-Adams MM, Romano TA, et al. Immune dysfunction in Atlantic bottlenose dolphins (Tursiops truncatus) with lobomycosis. Med Mycol 2009; 47:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paniz-Mondolfi AE, Sander-Hoffmann L. Lobomycosis in inshore and estuarine dolphins. Emerg Infect Dis 2009; 15:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bermudez L, Van Bressem MF, Reyes-Jaimes O, et al. Lobomycosis in man and lobomycosis-like disease in bottlenose dolphin, Venezuela. Emerg Infect Dis 2009; 15:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paniz-Mondolfi A. Lobomycosis: An aproach after 70 years. Dermatol Venez 2003; 41:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paniz-Mondolfi AE, Reyes Jaimes O, Dávila Jones L. Lobomycosis in Venezuela. Int J Dermatol 2007; 46:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosales T, Reyes Jaimes O, Reyes Flores O, et al. Keloidal and verrucous lesions in an Amerindian patient. Clin Exp Dermatol 2010; 35:e205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradinaud R. [Between Yucatan, Florida and French Guiana does lobomycosis exist in the Antilles?]. Bull Soc Pathol Exot Filiales 1984; 77:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradinaud R, Grosshans E, Basset M. [A new case of Jorge Lobo disease in French Guyana]. Bull Soc Fr Dermatol Syphiligr 1969; 76:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradinaud R, Joly F, Basset M, et al. [Chromomycosis and Jorge Lobo disease in French Guiana]. Bull Soc Pathol Exot Filiales 1969; 62:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garzón Aldás E, Herrera Vicuña V. Lobomicosis: una serie de 5 casos. Piel 2013; 28:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivas OR. Enfermedad de Jorge Lobo: primer caso diagnosticado en el Peru. Arch Peruanos Pat Clin 1972; 26:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talhari S, Cuba Caparo A, Ganter B. [Jorge Lobo's disease. Second Peruvian case]. Med Cutan Ibero Lat Am 1985; 13:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bustamante B, Seas C, Salomon M, Bravo F. Lobomycosis successfully treated with posaconazole. Am J Trop Med Hyg 2013; 88:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recacoechea M, Vargas J. Experiencia con el ketoconazole en el primer caso de lobomicosis en Bolivia. Bol Inf CENETROP 1982; 8:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HERRERA JM. [Paracoccidioides brasiliensis]. Arch Med Panamenos 1955; 4:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapia A, Torres-Calcindo A, Arosemena R. Keloidal blastomycosis (Lobo's disease) in Panama. Int J Dermatol 1978; 17:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca JJ. Lobomycosis. Int J Surg Pathol 2007; 15:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacaziosis (Jorge Lobo's disease): Review and update. An Bras Dermatol 2007; 82:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns RA, Roy JS, Woods C, et al. Report of the first human case of lobomycosis in the United States. J Clin Microbiol 2000; 38:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsayed S, Kuhn SM, Barber D, et al. Human case of lobomycosis. Emerg Infect Dis 2004; 10:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saint-Blancard P, Maccari F, Le Guyadec T, et al. [Lobomycosis: a mycosis seldom observed in metropolitan France]. Ann Pathol 2000; 20:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symmers WS. A possible case of Lôbo's disease acquired in Europe from a bottle-nosed dolphin (Tursiops truncatus). Bull Soc Pathol Exot Filiales 1983; 76:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer M, Chrusciak Talhari A, Reinel D, Talhari S. [Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease]. Hautarzt 2002; 53:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadavid E, Dalamaga M, Kapniari I, et al. Lobomycosis: A case from Southeastern Europe and review of the literature. J Dermatol Case Rep 2012; 6:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods WJ, Belone Ade F, Carneiro LB, Rosa PS. Ten years experience with Jorge Lobo's disease in the state of Acre, Amazon region, Brazil. Rev Inst Med Trop Sao Paulo 2010; 52:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talhari S, Talhari C. Lobomycosis. Clin Dermatol 2012; 30:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva D. Micose de Lobo. Rev Soc Bras Med Trop 1972; 6:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva D, De Brito A. Formas clínicas não usuais de micose de Lobo. An Bras Dermatol 1994; 69:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado PdA. Regressão espontânea de lesões maculosas na Blastomicose de Jorge Lobo. Acta Amazon 1972; 2:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilela R, Mendoza L, Rosa PS, et al. Molecular model for studying the uncultivated fungal pathogen Lacazia loboi. J Clin Microbiol 2005; 43:3657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azulay RD, Carneiro JA, Da Graça M, et al. Keloidal blastomycosis (Lobo's disease) with lymphatic involvement: a case report. Int J Dermatol 1976; 15:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opromolla DV, Belone AF, Taborda PR, Rosa PS. Lymph node involvement in Jorge Lobo's disease: report of two cases. Int J Dermatol 2003; 42:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda MF, Costa VS, Bittencourt Mde J, Brito AC. [Transepidermal elimination of parasites in Jorge Lobo's disease]. An Bras Dermatol 2010; 85:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Andrade LM, Azulay RD, Carneiro J. [Jorge Lobo mycosis(histopathological study)]. Hospital (Rio J) 1968; 73:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilani-Moreno FR, Belone AF, Soares CT, Opromolla DV. Immunohistochemical characterization of the cellular infiltrate in Jorge Lobo's disease. Rev Iberoam Micol 2005; 22:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda MF, Silva AJ. Vinyl adhesive tape also effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidioidomycosis. Diagn Microbiol Infect Dis 2005; 52:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talhari C, Chrusciak-Talhari A, de Souza JV, et al. Exfoliative cytology as a rapid diagnostic tool for lobomycosis. Mycoses 2009; 52:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carneiro FP, Maia LB, Moraes MA, et al. Lobomycosis: diagnosis and management of relapsed and multifocal lesions. Diagn Microbiol Infect Dis 2009; 65:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azulay RD, Carneiro Jde A, de Andrade LC. [Jorge Lobo blastomycosis. Etiology, experimental inoculation, immunology and pathology of the disease]. An Bras Dermatol 1970; 45:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasqualotto AC, Jaskulski Filho SD, Sena MG, et al. Posaconazole for lobomycosis. Braz J Infect Dis 2021; 25:101576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves FG, Rosa PS, de Farias Fernandes Belone A, et al. Multidrug Therapy for Leprosy Can Cure Patients with Lobomycosis in Acre State, Brazil: A Proof of Therapy Study. Am J Trop Med Hyg 2020; 104:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence DN, Ajello L. Lobomycosis in western Brazil: report of a clinical trial with ketoconazole. Am J Trop Med Hyg 1986; 35:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cucé LC, Wroclawski EL, Sampaio SA. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole. Int J Dermatol 1980; 19:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Londoño F. Blastomicosis queloidiana. A propósito de un caso tratado con anfotericina B. Med Cutan Ibero Lat Am 1968; 2:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes O, Goihman M, Goldstein C. Blastomicosis queloidiana o enfermedad de Jorge Lobo. Comunicacion previa sobre un caso observado. Dermatol Venez 1960; 2:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SILVERIE R, RAVISSE P, VILAR JP, MOULINS C. [Keloid blastomycosis or Jorge Lobo disease in French Guiana]. Bull Soc Pathol Exot Filiales 1963; 56:29.
          </a>
         </li>
         <li class="breakAll">
          Baruzzi RG, Azevedo RA. Doença de Jorge Lobo. In: Clínica de doenças tropicais e infecciosas, Meira DA (Ed), Interlivros, 1991. p.229.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva D. [Treatment of Lobo's disease with clofazimine (B 663)]. Bull Soc Pathol Exot Filiales 1978; 71:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talhari S, Cunha MG, Barros ML, Gadelha AD. [Jorge Lobo disease. Study of 22 new cases]. Med Cutan Ibero Lat Am 1981; 9:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudok van Heel WH. Successful treatment in a case of lobomycosis (Lobo's Disease) in Tursiops truncatus (Mont) at Dolfinarium, Harderwijk. Aquat Mamm 1977; 5:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baruzzi RG, d'Andretta C Jr, Carvalhal S, et al. [Occurrence of keloidal blastomycosis among Caiabi Indians]. Rev Inst Med Trop Sao Paulo 1967; 9:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nogueira L, Mendes L, Rodrigues CA, et al. Lobomycosis and squamous cell carcinoma. An Bras Dermatol 2013; 88:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baruzzi RG, Rodrigues DA, Michalany NS, Salomão R. Squamous-cell carcinoma and lobomycosis (Jorge Lobo's disease). Int J Dermatol 1989; 28:183.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15883 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : da Lacaz CS, Porto E, Martins JE, et al. Doença de Jorge Lobo. In: Tratado de Micologia Médica Lacaz, 9th ed, Sarvier, 2002. p.462.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Contribuição para o conhecimento das granulomatoses blastomicoides. O agente etiológico da doença de Jorge Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Contribuição para o conhecimento das granulomatoses blastomicoides. O agente etiológico da doença de Jorge Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Contribuição para o conhecimento das granulomatoses blastomicoides. O agente etiológico da doença de Jorge Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Blastomicose "tipo Jorge Lobo"
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Blastomicose "tipo Jorge Lobo"
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lobomicosis: nomenclatura de su agente (revisión critica)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10325371" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lacazia loboi gen. nov., comb. nov., the etiologic agent of lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429689" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lobomycosis: an emerging disease in humans and delphinidae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18651310" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Enzymatic isolation of Lacazia loboi cells from skin lesions of lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19220901" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Accidental Jorge Lobo's disease in a worker dealing with Lacazia loboi infected mice: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Lobomicosis experimental
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Blastomicosis queloidiana o enfermedad de Jorge Lobo en Venezuela
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10887368" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Inoculation of Lacazia loboi into the subcutaneous tissue of the hamster cheek pouch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27869614" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cutaneous Granulomas in Dolphins Caused by Novel Uncultivated Paracoccidioides brasiliensis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/539528" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Study of humoral and cellular immunity in lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208026" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection of cytokines and nitric oxide synthase in skin lesions of Jorge Lobo's disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15804285" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Transforming growth factor-beta1 enhances the interferon-gamma-dependent, interleukin-12-independent pathway of T helper 1 cell differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20510345" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Immunohistochemical evaluation of macrophage activity and its relationship with apoptotic cell death in the polar forms of leprosy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26700881" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Analysis of Immune Response Markers in Jorge Lobo's Disease Lesions Suggests the Occurrence of Mixed T Helper Responses with the Dominance of Regulatory T Cell Activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3242380" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cellular immunity in lobomycosis (keloidal blastomycosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17959227" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Macrophage and TGF-beta immunohistochemical expression in Jorge Lobo's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096202" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lobomycosis. Literature review and future perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5787929" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : [The reservoir area of lobomycosis. Comments on the work of Dr. Carlos Peña on 2 Colombian cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Um caso de blastomicose, produzido por uma espécie nova, encontrada em Recife
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32310067" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Epidemiologic and Clinical Progression of Lobomycosis among Kaiabi Indians, Brazil, 1965-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8505156" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Enfermedad de Jorge Lobo o blastomicosis queloidiana. Nuevos aspectos de la entidad en Colombia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1480207" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lobomycosis in Colombian Amer Indian patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18608890" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Immune dysfunction in Atlantic bottlenose dolphins (Tursiops truncatus) with lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19331770" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lobomycosis in inshore and estuarine dolphins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19751598" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lobomycosis in man and lobomycosis-like disease in bottlenose dolphin, Venezuela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lobomycosis: An aproach after 70 years
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17269972" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lobomycosis in Venezuela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20518918" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Keloidal and verrucous lesions in an Amerindian patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6488429" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : [Between Yucatan, Florida and French Guiana does lobomycosis exist in the Antilles?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5384220" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : [A new case of Jorge Lobo disease in French Guyana].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5409181" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : [Chromomycosis and Jorge Lobo disease in French Guiana].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lobomicosis: una serie de 5 casos
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Enfermedad de Jorge Lobo: primer caso diagnosticado en el Peru
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3906310" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : [Jorge Lobo's disease. Second Peruvian case].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23546805" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Lobomycosis successfully treated with posaconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Experiencia con el ketoconazole en el primer caso de lobomicosis en Bolivia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13303866" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : [Paracoccidioides brasiliensis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/689802" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Keloidal blastomycosis (Lobo's disease) in Panama.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172499" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Lacaziosis (Jorge Lobo's disease): Review and update
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699043" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Report of the first human case of lobomycosis in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200867" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Human case of lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891722" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : [Lobomycosis: a mycosis seldom observed in metropolitan France].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6231133" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A possible case of Lôbo's disease acquired in Europe from a bottle-nosed dolphin (Tursiops truncatus).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12297950" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23091581" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lobomycosis: A case from Southeastern Europe and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21049233" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Ten years experience with Jorge Lobo's disease in the state of Acre, Amazon region, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22682191" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Micose de Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Formas clínicas não usuais de micose de Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Regressão espontânea de lesões maculosas na Blastomicose de Jorge Lobo
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16081893" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Molecular model for studying the uncultivated fungal pathogen Lacazia loboi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/942708" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Keloidal blastomycosis (Lobo's disease) with lymphatic involvement: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14636186" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lymph node involvement in Jorge Lobo's disease: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20464085" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : [Transepidermal elimination of parasites in Jorge Lobo's disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4899938" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : [Jorge Lobo mycosis(histopathological study)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15813683" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Immunohistochemical characterization of the cellular infiltrate in Jorge Lobo's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15878441" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Vinyl adhesive tape also effective for direct microscopy diagnosis of chromomycosis, lobomycosis, and paracoccidioidomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18705665" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Exfoliative cytology as a rapid diagnostic tool for lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19679237" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Lobomycosis: diagnosis and management of relapsed and multifocal lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5507908" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : [Jorge Lobo blastomycosis. Etiology, experimental inoculation, immunology and pathology of the disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33857497" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Posaconazole for lobomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33200722" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Multidrug Therapy for Leprosy Can Cure Patients with Lobomycosis in Acre State, Brazil: A Proof of Therapy Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3946734" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Lobomycosis in western Brazil: report of a clinical trial with ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6252105" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Blastomicosis queloidiana. A propósito de un caso tratado con anfotericina B
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Blastomicosis queloidiana o enfermedad de Jorge Lobo. Comunicacion previa sobre un caso observado
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13992935" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : [Keloid blastomycosis or Jorge Lobo disease in French Guiana].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13992935" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : [Keloid blastomycosis or Jorge Lobo disease in French Guiana].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/755535" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : [Treatment of Lobo's disease with clofazimine (B 663)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7026930" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : [Jorge Lobo disease. Study of 22 new cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Successful treatment in a case of lobomycosis (Lobo's Disease) in Tursiops truncatus (Mont) at Dolfinarium, Harderwijk
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5604165" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : [Occurrence of keloidal blastomycosis among Caiabi Indians].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23739701" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lobomycosis and squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2707943" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Squamous-cell carcinoma and lobomycosis (Jorge Lobo's disease).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
